Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers

A method of treatment of a condition which is modulated by RAF kinases, wherein the condition is selected from the group consisting of cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma and leukemia, wherein the method comprises administering to a patient in need thereof a therapeutic amount of a compound of formula (I):

• wherein:
• the bond between Y and Z is a single bond or a double bond;
• A is a phenyl ring;
• R1 is a substituted or unsubstituted heterocyclic moiety which either contains 5 or 6 atoms in a single ring or 8, 9, 10 or 11 atoms in a fused bicyclic ring system, when substituted R1 contains 1 to 4 substituents independently selected from the group consisting of halo, —ORA, —NRARB, ═O, —OC(O)RC, —C(O)RC, —C(O)ORA, —NRAC(O)RC, —C(O)NRARB, —SO2RC, —SORC, —NRASO2RC, —SO2NRARB, —CN, C1-4 alkyl, C1-4 haloalkyl and C3-6 cycloalkyl;
• X is O;
• Y is —CHW and the bond between Y and Z is a single bond;
• or Y is —CW and the bond between Y and Z is a double bond;
• W represents -het1-R3 or -het2, in which het1 is an optionally further substituted five or six membered cycloalkyl ring or heterocyclic ring, and het2 is a carbocyclic or heterocyclic ring system containing 8, 9 or 10 atoms in a fused bicyclic ring system;
• in which het2 is unsubstituted or substituted;
• and het1, when further substituted, and het2 when substituted contain 1 or 2 substituents independently selected at each occurrence from halo, —ORA, —CN, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, in which the aforementioned alkyl, haloalkyl and cycloalkyl groups are themselves unsubstituted or substituted with 1 to 3 groups independently selected from the group consisting of —ORA, —CN, and —NRARB;
• Z is O, or —CH2 and the bond between Y and Z is a single bond:
• or Z is —CH and the bond between Y and Z is a double bond;
• R2A is selected from the group consisting of H, halo, —ORA, —CN, C1-4 alkyl, C1-4 haloalkyl and C3-6 cycloalkyl;
• R3 is selected from the group consisting of substituted or unsubstituted:
• C1-6 alkyl, C1-6 haloalkyl, a carbocyclic moiety or a heterocyclic moiety, wherein the carbocyclic moiety and heterocyclic moiety either contain 5 or 6 atoms in a single ring or 8, 9 or 10 atoms in a fused bicyclic ring system, and when substituted R3 contains 1 to 4 substituents independently selected from the group consisting of halo, —ORA, —NRARB, —SO2RC, —SORC, —CN, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl in which the aforementioned alkyl, haloalkyl and cycloalkyl groups are themselves unsubstituted or substituted with 1 to 3 groups independently selected from the group consisting of —ORA, —CN, —SORC and —NRARB;
• RA and RB are each independently selected from H, C1-4 alkyl and C1-4 haloalkyl;
• and
• RC is selected from C1-4 alkyl and C1-4 haloalkyl.